Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.

@article{Lpez2005EfficacyOM,
  title={Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.},
  author={Francisco Zamora L{\'o}pez and Pablo Parker and Auayporn P. Nademanee and Roberto R Rodr{\'i}guez and Zaid Al-Kadhimi and Ravi Bhatia and Sandra R Cohen and Peter Falk and Henry Hoi Tai Fung and Mark H. Kirschbaum and Amrita Y. Krishnan and Neil M Kogut and Arturo Molina and Ryotaro Nakamura and Margaret O'donnell and Leslie L Popplewell and Vinod Pullarkat and Joseph Rosenthal and Firoozeh Sahebi and E OʼBrian Smith and David Snyder and George Somlo and Ricardo T. Spielberger and Anthony Stein and Robert Sweetman and Jasmine M. Zain and Stephen Forman},
  journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation},
  year={2005},
  volume={11 4},
  pages={307-13}
}
Current treatment of chronic graft-versus-host disease (cGVHD) with prednisone (PSE) alone or with added cyclosporine or tacrolimus still has a very high failure and complication rate, and new treatment approaches are needed for both primary and salvage therapy. Mycophenolate mofetil (MMF) is an immunosuppressive agent currently in use for acute graft… CONTINUE READING